Summary
Heparin added together with murine L cell interferon inhibited the development of antiviral activity in mouse L cells. When added after interferon treatment, heparin had no effect on antiviral activity. There was also no inhibition of interferon action in L cells treated with heparin before addition of interferon. On the other hand, heparin did not inhibit antiviral activities of human interferon α and β. Since murine L cell interferon, but not human interferon α and β, binds to a heparin affinity column and can be eluted with a solution of high salt, it is presumed that murine L cell interferon and heparin must interact with each other. The apparent interaction of heparin with murine L cell interferon was prevented by protamine, a drug that neutralizes heparin. Dextran sulfate inhibited murine L cell interferon action, but dextran and chondroitin sulfate A did not. These results suggests that heparin inhibited murine L cell interferon action by the binding via sulfate groups on its molecules. Heparin also inhibited antiviral activity of murine L cell interferon in mice infected with herpes simplex virus (+GC Miyama strain).
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Aguet, M.: High-affinity binding of125I-labelled mouse interferon to a specific cell surface receptor. Nature284, 459–461 (1980).
Aguet, M., Belardelli, F., Blanchard, B., Marcucci, F., Gresser, I.: High-affinity binding of125I-labeled mouse interferon to a specific cell surface receptor. IV. Mouse γ interferon and cholera toxin do not compete for the common receptor site of α/β interferon. Virology117, 541–544 (1982).
Aguet, M., Blanchard, B.: High affinity binding of125I-labeled mouse interferon to a specific cell surface receptor. II. Analysis of binding properties. Virology115, 249–261 (1981).
Anderson, P., Yip, Y. K., Vilcek, J.: Specific binding of125I-human interferon-γ to high affinity receptors on human fibroblasts. J. Biol. Chem.257, 11301–11304 (1982).
Besancon, F., Ankel, H.: Inhibition of interferon action by plant lectins. Nature250, 784–786 (1974).
Blalock, J. E., Gifford, G. E.: Inhibition of interferon action by Vitamine A. J. gen. Virol.29, 315–324 (1975).
Borden, E. C., Murphy, F. A., Gary, B. W. jr.: Attempted suppression of the interferon response in the mouse. Proc. Soc. Exp. Biol. Med.134, 865–869 (1970).
Branca, A. A., Baglioni, C.: Evidence that types I and II interferons have different receptors. Nature294, 768–770 (1981).
Davey, M. W., Huang, J. W., Sulkowski, E., Carter, W. A.: Hydrophobic binding sites on human interferon. J. Biol. Chem.250, 348–349 (1975).
Ehrlich, J., Stivala, S. S.: Chemistry and pharmacology of heparin. J. Pharmac. Sci.62, 517–544 (1973).
Faltynek, C. R., Branca, A. A., McCandless, S., Baglioni, C.: Characterization of an interferon receptor on human lymphoblastoid cells. Proc. Natl. Acad. Sci. (U.S.A.)80, 3269–3273 (1983).
Friedman, R. M.: Interferon Vol. 1, 53–74. Academic Press 1979.
Friedman, R. M., Kohn, L. D.: Cholera toxin inhibits interferon action. Biochem. Biophys. Res. Commun.70, 1078–1084 (1976).
Huang, L. W., Davey, M. W., Helna, C. J., Muenchhausen, W., Sulkowski, E., Carter, W. A.: Selective binding of human interferon to albumin immobilized on agarose. J. Biol. Chem.249, 4665–4667 (1974).
Gresser, I., Tovey, M. G., Maury, C., Bandu, M. T.: Role of interferon on the pathogenesis of virus disease in mice as demonstrated by the use of anti-interferon serum. II. Studies with Herpes Simplex, Molony Sarcoma, Vesicular Stomatitis, New-castle Disease and Influenza Viruses. J. Exp. Med.144, 1316–1323 (1976).
Kato, N., Eggers, H. J.: Depressors of interferon synthesis: Inhibition of interferon synthesis by chick allantoic mucopolysaccharide, capsular polysaccharide ofKlebsiella pneumoniae and heparin. J. gen. Virol.5, 369–377 (1969).
Knight, E. jr., Hunkapiller, M. W., Korant, B. D., Hardy, R. W. F., Hood, L. E.: Human fibroblast interferon: Amino acid analysis and amino terminal amino acid sequence. Nature207, 525–526 (1980).
Kohn, L. D., Friedman, R. M., Holmes, J. M., Lee, G.: Use of thyrotropin and cholera toxin to probe the mechanism by which interferon initiates its antiviral activity. Proc. Natl. Acad. Sci. (U.S.A.)73, 3695–3699 (1976).
Krishnamurti, C., Besancon, F., Justensen, J., Poulsen, K., Ankel, H.: Inhibition of mouse fibroblast interferon by gangliosides. Differential effects on biological activity and on induction of (2′–5′) oligoadenylate synthetase. Eur. J. Biochem.124, 1–6 (1982).
Sakai, A., Ebina, T., Ishida, N.: Interferon induction in mice by oral administration of K-582, a new peptide antibiotic. J. Antibiotics36, 335–338 (1983).
Stewart, W. E., II: The Interferon System, 134–183. Wien-New York: Springer-Verlag 1979.
Sydiskis, R. J., Schultz, I.: Interferon and antibody production in mice with herpes simplex skin infections. J. Infec. Dis.116, 455–460 (1966).
Taira, H., Broeze, R. J., Jayaran, B. M., Lengyel, P., Hunkapiller, M. W., Hood, L. E.: Mouse interferons: Amino terminal amino acid sequences of various species. Nature207, 528–530 (1980).
Vengris, V. E., Reynolds, F. H. jr., Hollenberg, M. D., Pitha, P. M.: Interferon action: Role of membrane gangliosides. Virology72, 486–493 (1976).
Yoshikura, H.: Dependence of murine sarcoma virus infection of the cell cycle. J. gen. Virol.6, 183–185 (1970).
Zoon, K., Nedden, D. Z., Arnheiter, H.: Specific binding of human α interferon to a high affinity cell surface binding site on bovine kidney cells. J. Biol. Chem.257, 4695–4697 (1982).
Zoon, K. C., Smith, M. E., Bridgen, P. J., Anfinsen, C. B., Hunkapiller, M. W., Hood, L. E.: Amino terminal sequence of the major component of human lymphoblastoid interferon. Nature207, 527–528 (1980).
Author information
Authors and Affiliations
Additional information
With 6 Figures
Rights and permissions
About this article
Cite this article
Sakai, A., Ebina, T. & Ishida, N. Inhibition of murine L cell interferon action by heparin. Archives of Virology 90, 73–85 (1986). https://doi.org/10.1007/BF01314146
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01314146